Atherosclerosis is the pathological basis of most cardiovascular diseases,the leading cause of morbidity and mortality worldwide.Kallistatin,originally discovered in human serum,is a tissuekallikrein-binding protein and a unique serine proteinase inhibitor.Upon binding to its receptor integrin β3,lipoprotein receptor-related protein 6,nucleolin,or Krüppel-like factor 4,kallistatin can modulate various signaling pathways and affect multiple biological processes,including angiogenesis,inflammatory response,oxidative stress,and tumor growth.Circulating kallistatin levels are significantly decreased in patients with coronary artery disease and show an inverse correlation with its severity.Importantly,both in vitro and in vivo experiments have demonstrated that kallistatin reduces atherosclerosis by inhibiting vascular inflammation,antagonizing endothelial dysfunction,and improving lipid metabolism.Thus,kallistatin may be a novel biomarker and a promising therapeutic target for atherosclerosis-related diseases.In this review,we focus on the antiatherogenic function of kallistatin and its potential mechanism.
展开▼
